



ASX Announcement

27 July 2020

Elixinol Global continues to deliver on its strategy to build a global Elixinol branded CBD nutraceuticals business

- **PharmaCann to distribute Elixinol hemp derived CBD products in Australia under the Therapeutic Goods Administration's Special Access Scheme**
- **Potential for accelerated sales should descheduling of CBD come into effect**

Elixinol Global Limited (**Elixinol Global** or the **Company**) (**ASX:EXL; OTC:ELLXF**) is pleased to announce that the first order has been made under an exclusive distribution agreement with PharmaCann Pty Ltd (**PharmaCann**). PharmaCann will sell Elixinol cannabidiol (**CBD**) products in the Australian market through the Therapeutic Goods Administration's (**TGA's**) Special Access Scheme (**SAS**). This is a significant milestone for the Company's growth strategy in Australia following PharmaCann having obtained the necessary regulatory and governmental approvals to import and wholesale all forms of medicinal cannabis.

The Elixinol Global and PharmaCann agreement enables PharmaCann to import and supply Elixinol branded CBD products into Australia. The TGA has recently consulted on the proposed descheduling of CBD products. Should the TGA deschedule CBD early in 2021 as proposed, it would allow CBD products to be prescribed over the counter by pharmacists. This will make CBD products become widely available for consumers in Australian pharmacies.

PharmaCann is a licensed medicinal cannabis and CBD products wholesaler in Australia and New Zealand, servicing a network of over 1,600 medical practitioners and over 2,000 pharmacies. PharmaCann's business model is based on distributing medicinal cannabis / CBD products under the TGAs SAS through a direct marketing and education model targeted at doctors and pharmacists. PharmaCann currently has access to a growing network of over 130 prescribing doctors and holds licenses to import, export and wholesale medicinal cannabis.

PharmaCann dispenses its medicinal cannabis products through all major pharmacy chains including Chemist Warehouse, TerryWhite Chemmart, Priceline Pharmacy, Chempro, Ramsay Health, Direct Chemist Outlets, Discount Drug Stores, Good Price Pharmacy and multiple independent pharmacies across Australia.

Group CEO, Oliver Horn, commented, "We regularly receive queries about whether our products are accessible in Australia, so we're very pleased to now be able to offer a solution. The relationship with PharmaCann gives us the ability to sell Elixinol branded products in our home market in a way which fits within current regulations."

For personal use only



Victor Caprio, Managing Director of PharmaCann Global says, “PharmaCann is proud to be working with Elixinol Global to continue our program aiming to deliver the most affordable, high-quality cannabinoid medicines across Australia and New Zealand, and to continue working with our Medical Network to ensure sustainable accessibility to medicinal cannabis overall. At PharmaCann, our ethos is to ensure that all members of our communities have a streamlined access to the most affordable cannabinoid medicines in the market. By working with Elixinol Global to distribute their products in the region, the continuation of our program on delivering affordable, high quality medicines can be met.”

The Company looks forward to keeping shareholders updated.

This document was authorised to be given to the ASX by the Board of the Company.

For more information please contact:

Ron Dufficy
Chief Financial Officer
ron.dufficy@elixinolglobal.com

About Elixinol Global

Elixinol Global Limited (ASX:EXL; OTC:ELLXF) is a global leader in the hemp derived CBD industry, innovating, manufacturing and selling hemp derived CBD products. The Company’s simplified business model is focusing on:

- In the Americas, innovating, manufacturing and selling high quality Elixinol branded hemp derived CBD products based in Colorado, USA
- In Europe & UK, educating and selling high quality Elixinol branded and co-branded hemp derived CBD products based in Amsterdam, The Netherlands
- In Australia, providing stronger unified planning and support across the group to enable the various regional offices to focus on operational strategy and execution through its Global Executive Office based in Sydney, Australia
- Across the Rest of World, expanding distribution of Elixinol branded hemp derived CBD products through reputable distributors as key markets open.

See more at www.elixinolglobal.com

About PharmaCann

PharmaCann Global is a licensed medicinal cannabis Wholesaler in Australia and soon New Zealand, with expanding operations to include Manufacturing, with the ability to distribute throughout Australia, New Zealand, and beyond. Our Team works closely with Doctors, Hospitals, Pharmacists, Compounders and Manufacturers to ensure patients have access to affordable, high quality medicine.

See more at <https://www.pharmacann.com.au/>

For personal use only